Success Metrics

Active Trials
7(88%)

Phase Distribution

Ph phase_1
4
50%
Ph phase_2
2
25%
Ph phase_3
1
13%
Ph phase_4
1
13%

Phase Distribution

4

Early Stage

2

Mid Stage

2

Late Stage

Phase Distribution8 total trials
Phase 1Safety & dosage
4(50.0%)
Phase 2Efficacy & side effects
2(25.0%)
Phase 3Large-scale testing
1(12.5%)
Phase 4Post-market surveillance
1(12.5%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

7

trials recruiting

Total Trials

8

all time

Status Distribution
Active(8)

Detailed Status

Recruiting5
Active, not recruiting2
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
8
Active
7
Success Rate
N/A
Most Advanced
Phase 4

Trials by Phase

Phase 14 (50.0%)
Phase 22 (25.0%)
Phase 31 (12.5%)
Phase 41 (12.5%)

Trials by Status

recruiting563%
not_yet_recruiting113%
active_not_recruiting225%

Recent Activity

7 active trials
Showing 5 of 8
recruitingphase_2

Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

NCT05489211
recruitingphase_1

Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies

NCT05417594
recruitingphase_4

An Open-label, Single-arm Study of Prophylaxis for Datopotamab Deruxtecan (Dato-DXd) -Related Stomatitis in Eligible Patients With Metastatic or Inoperable Locally Recurrent Breast Cancer or Locally Advanced or Metastatic Epidermal Growth Factor Receptor-Mutated Non-small Cell Lung Cancer.

NCT07357597
not_yet_recruitingphase_1

GB268 Monotherapy or Combination Therapy for Locally Advanced/Metastatic Breast Cancer (Phase Ib/Ⅱ)

NCT07738341
active_not_recruitingphase_1

A Study of Dato-DXd in Chinese Patients With Advanced Non-Small Cell Lung Cancer, Triple-negative Breast Cancer and Other Solid Tumors (TROPION-PanTumor02)

NCT05460273
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT05489211Phase 2

Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

Recruiting
NCT05417594Phase 1

Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies

Recruiting
NCT07357597Phase 4

An Open-label, Single-arm Study of Prophylaxis for Datopotamab Deruxtecan (Dato-DXd) -Related Stomatitis in Eligible Patients With Metastatic or Inoperable Locally Recurrent Breast Cancer or Locally Advanced or Metastatic Epidermal Growth Factor Receptor-Mutated Non-small Cell Lung Cancer.

Recruiting
NCT07738341Phase 1

GB268 Monotherapy or Combination Therapy for Locally Advanced/Metastatic Breast Cancer (Phase Ib/Ⅱ)

Not Yet Recruiting
NCT05460273Phase 1

A Study of Dato-DXd in Chinese Patients With Advanced Non-Small Cell Lung Cancer, Triple-negative Breast Cancer and Other Solid Tumors (TROPION-PanTumor02)

Active Not Recruiting
NCT07291037Phase 3

Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations

Recruiting
NCT06954480Phase 2

Investigating Datopotamab Deruxtecan Plus Durvalumab Versus Datopotamab Deruxtecan in Patients With PDL1-negative Metastatic Triple-negative Breast Cancer

Recruiting
NCT03401385Phase 1

First-in-human Study of DS-1062a for Advanced Solid Tumors (TROPION-PanTumor01)

Active Not Recruiting

All 8 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
8